SI-Bone AI Stock Analysis
Want to see SIBN full AI Analyst Report?
SI-Bone (SIBN) AI Stock Analysis
SI-Bone
(NASDAQ:SIBN)
The score is driven primarily by improving (but still not fully profitable) financial performance and a strongly positive earnings call with reaffirmed guidance and better operating leverage, supported by bullish technical trends. Valuation remains a meaningful constraint due to ongoing net losses and a negative P/E.
SI-Bone (SIBN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.06B
- Dividend Yield
- ―
- Average Volume (3M)
- 713.88K
- Price to Earnings (P/E)
- -76.0
- Beta (1Y)
- 0.47
- Revenue Growth
- 13.99%
- EPS Growth
- 39.54%
- Country
- US
- Employees
- 376
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
SI-Bone Business Overview & Revenue Model
Company Description
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its fl...
How the Company Makes Money
SI-Bone primarily makes money by selling its SI joint fusion implant systems and associated surgical instruments used in procedures performed in hospitals and ambulatory surgery centers. Revenue is generated largely from product sales per procedure (...
SI-Bone Earnings Call Summary
The call was strongly positive. Highlights significantly outweighed the lowlights, with approximately 15% worldwide revenue growth, 20% U.S. procedure-volume growth, 32.4% adjusted EBITDA growth, stronger operating cash flow, reaffirmed revenue guidance and strong early Onyx demand. The main challenges were lower ASP from mix, the continued net loss, expected modest gross margin pressure in 2027 and the need for additional clinical data and finalized reimbursement decisions.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
SI-BONE reaffirmed 2026 worldwide revenue guidance of $231 million to $233 million and gross margin expectations at 79%, while now expecting operating expenses to grow 10.5% versus its prior expectation of 12%; the midpoint of annual worldwide revenue guidance implies over 20% year-over-year revenue growth in the fourth quarter, with Onyx expected to make a modest contribution in the fourth quarter and full launch expected in January, and the company is targeting to exit 2026 with nearly 100 territories. Long term, operating leverage is expected to be 1.25x revenue growth to OpEx growth on the low end and as high as 1.75x over the long term, with the midpoint of the leverage being around 1.4x, 1.5x, while gross margin is expected to be in sort of that 78% area as you go beyond 2027; if approved, Onyx NTAP would take effect on October 1, 2027.
SI-Bone Financial Statement Overview
Summary
Financials show clear improvement but not full durability yet: revenue scaled materially over multiple years and losses have narrowed significantly, with operating cash flow turning positive in TTM. Offsetting this, the company remains net-loss and operating-loss making, free cash flow is still negative, and the most recent TTM revenue growth decelerated sharply.
Income Statement
62PositiveBalance Sheet
68PositiveCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 220.65M | 200.93M | 167.18M | 138.89M | 106.41M | 90.15M |
| Gross Profit | 175.19M | 159.88M | 132.12M | 109.42M | 90.70M | 79.72M |
| EBITDA | -3.91M | -10.91M | -23.09M | -34.45M | -54.98M | -50.97M |
| Net Income | -13.69M | -18.91M | -30.91M | -43.34M | -61.26M | -56.57M |
Balance Sheet | ||||||
| Total Assets | 256.77M | 238.56M | 230.44M | 230.43M | 157.55M | 190.51M |
| Cash, Cash Equivalents and Short-Term Investments | 146.26M | 147.82M | 150.04M | 166.02M | 97.29M | 146.98M |
| Total Debt | 42.80M | 1.12M | 37.48M | 38.99M | 39.43M | 40.48M |
| Total Liabilities | 72.09M | 61.02M | 63.47M | 61.05M | 59.25M | 56.09M |
| Stockholders Equity | 184.68M | 177.53M | 166.96M | 169.38M | 98.30M | 134.42M |
Cash Flow | ||||||
| Free Cash Flow | -4.19M | -9.09M | -22.92M | -26.51M | -51.16M | -45.92M |
| Operating Cash Flow | 6.08M | -675.00K | -12.43M | -18.71M | -41.66M | -39.53M |
| Investing Cash Flow | -24.00K | 4.16M | 12.62M | -59.80M | -2.81M | 51.58M |
| Financing Cash Flow | 3.04M | 3.38M | 1.96M | 90.93M | 2.20M | -1.71M |
SI-Bone Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SIBN, the sentiment is Positive. The current price of 23.54 is above the 20-day moving average (MA) of 23.10, above the 50-day MA of 20.67, and above the 200-day MA of 16.86, indicating a bullish trend. The MACD of 0.95 indicates Positive momentum. The RSI at 56.64 is Neutral, neither overbought nor oversold. The STOCH value of 15.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SIBN.
SI-Bone Risk Analysis
SI-Bone disclosed 61 risk factors in its most recent earnings report. SI-Bone reported the most risks in the "Production" category.
Latest Risks Added
3 New RisksSI-Bone Peers Comparison
Overall Rating
GMED73Outperform
SIBN70Outperform
ZBH69Neutral
ATEC50Neutral
OFIX44Neutral
XTNT39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $9.27B | 17.04 | 11.82% | ― | 13.35% | 32.22% | |
| 70Outperform | $1.04B | -75.98 | -7.57% | ― | 13.99% | 39.54% | |
| 69Neutral | $19.32B | 26.02 | 6.05% | 0.93% | 6.98% | -2.22% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $1.10B | -12.61 | -547.17% | ― | 15.34% | 46.31% | |
| 44Neutral | $269.42M | -5.92 | -10.32% | ― | 2.12% | 63.59% | |
| 39Underperform | $28.82M | -1.76 | -36.21% | ― | -24.44% | -1012.80% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SIBN | Si-Bone | 23.54 | 4.86 | 26.02% | |
| ATEC | Alphatec | 7.06 | -12.55 | -64.00% | |
| OFIX | Orthofix Medical Inc. | 6.61 | -7.68 | -53.74% | |
| ZBH | Zimmer Biomet Holdings | 103.32 | 15.19 | 17.24% | |
| GMED | Globus Medical | 70.53 | -11.75 | -14.28% | |
| XTNT | Xtant Medical Holdings Inc | 0.20 | -0.44 | -68.36% |
SI-Bone Corporate Events
SI-BONE Announces Voluntary Recall of iFuse TORQ Implants
NegativeOn August 21, 2026, SI-BONE initiated a voluntary recall of 98 iFuse TORQ implants whose tube packaging, manufactured between May 4 and May 15, 2026, failed to consistently meet sterile barrier criteria, creating a potential infection risk and possib...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
